Clinical Efficacy and Safety of Teriparatide Versus Alendronate in Postmenopausal Osteoporosis: A Systematic Review of Randomized Controlled Trials.

Alendronate, a second-generation bisphosphonate, remains the first-line therapeutic option for postmenopausal osteoporosis. It acts on the bone resorbing osteoclasts causing their apoptosis. This is achieved by producing toxic adenosine triphosphate (ATP) analogues and interfering with the mevalonate pathway.